EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Letter to the Editor: Serum chitinase-3-like protein 1 as a biomarker in liver disease: Concerns regarding postoperative recurrence and hepatitis-related confounding

Chang-Zhi Chen, Lin Li, Jing-Feng Qiu

World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)

DOI: 10.4251/wjgo.124077 ↗
AbstractBibliografische Angaben

Abstract

With great interest, we read the article by Zhang et al entitled “Diagnostic value of serum chitinase-3-like protein 1 for liver fibrosis/cirrhosis and hepatocellular carcinoma” published in the World Journal of Gastrointestinal Oncology . This retrospective study evaluated the diagnostic and prognostic value of serum chitinase-3-like protein 1 (CHI3 L1) in liver fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and postoperative recurrence. We commend the authors for their important contribution in developing a novel serological biomarker for liver diseases. However, there are still several issues that need to be addressed in this study. The study suggests that serum CHI3 L1 can be used to monitor patients after hepatectomy and identify postoperative recurrence. However, it may be necessary to provide and compare serum CHI3 L1 data from HCC patients after curative resection (without recurrence) with the serological data from patients with postoperative recurrence, to better support this conclusion. In this study, patients with cirrhosis, HCC and postoperative recurrence were included. These populations are frequently accompanied by underlying hepatitis, which may affect serum CHI3 L1 levels and potentially confound the results. This overlap in disease etiologies and inflammatory activity might also help explain the relatively low diagnostic performance observed in the receiver operating characteristic analysis shown in Figure 1 .

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →